GEM is an investment group that provides a diversified portfolio of asset classes spanning the global private investing spectrum. GEM offers investment vehicles with different degrees of operational control, risk-adjusted return, and liquidity profiles.

Christopher Brown

Global Emerging Markets ("GEM") was founded in 1991. Our firm is a $3.4 billion alternative investment group that manages a diverse set of investment vehicles focused on emerging markets across the world.
The partners have a century of collective experience and as a group have invested in 265 companies across 55 countries. GEM's investment vehicles provide the group and its investors with a diversified portfolio of asset classes that span the global private investing spectrum.

Intertainment Media

PYX Resources

Relief Therapeutics

WISeKey

Northcore Technologies

Cytocom

DWC 3.0

Ensysce Biosciences

YuuZoo Corporation

The Global Emerging Markets Group (GEM)

GEM Portfolio Company, FibroBiologics completes Direct Listing on NASDAQ
- 

About FibroBiologics
Based in Houston, FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.

GEM Portfolio Company, GRIID to Begin Trading on Nasdaq Global Market Under Ticker “GRDI”
-
About GRIID Infrastructure Inc.
GRIID is a purpose-built bitcoin mining company, founded in 2018, that has operated mining facilities since 2019. GRIID has built long-term power relationships securing affordable, reliable, environmentally responsible power, enabling a vertically integrated self-mining business model with significant growth opportunity. Headquartered in Cincinnati, Ohio, GRIID operates a R&D center in Austin, Texas and a development, deployment and equipment repair center in Rutledge, Tennessee. GRIID currently maintains mining facilities in Watertown, New York; Limestone, Maynardville and Lenoir City, Tennessee. To learn more, please visit www.griid.com.

GEM Portfolio Company, FibroBiologics to go Public Through Direct Listing on Nasdaq 
-
About FibroBiologics
Based in Houston, Texas, FibroBiologics is a regenerative medicine company developing an innovative solution for chronic disease treatment using fibroblast cells. Currently, FibroBiologics holds 150+ U.S. and International issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Orthopedics, Multiple Sclerosis, and Cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. Visit www.FibroBiologics.com

GEM commits $250m to SGP BioEnergy
-
About SGP BioEnergy
SGP BioEnergy is a bioenergy development pioneer on a mission to revolutionize how the world consumes energy sustainably. Founded by bioenergy pioneer Randy Delbert Letang, SGP BioEnergy, is a New York-based, integrated bioenergy products development company that has a plan to power the world with low carbon emitting fuels, energy and products for the next 100 years through an intelligent and integrated system. Unfettered by ties to the traditional oil sector, we've assembled a powerhouse network of partners across agriculture, finance, manufacturing, and technology. We're not just imagining a cleaner future — we're making it happen for a growing roster of forward-thinking clients committed to sustainability.

Metric
Company Name	GEM
Symbol
MSH ID	COM:GEMNY
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Investment Management
Country	US
Stage	Series A
Employee Count	11
Website	gemny.com
LinkedIn	the-global-emerging-markets-group-gem-
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital	23M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:GEMNY

GEM

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue